(GluEsk) Glutamate and Esketamine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-14

Study Completion Date

2025-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Esketamine is the S-enantiomer of racemic ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist. Esketamine and other antidepressant NMDA receptor antagonists are hypothesised to act by producing a rapid increase in brain glutamate release, which then stimulates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This activity in turn is thought to restore synaptic functioning, neuroplasticity, and connectivity in brain regions involved in mood regulation, which would be ultimately responsible for the antidepressant effect of esketamine. However, the effect of esketamine on glutamate release in humans has not previously been studied. In this study we therefore aim to ascertain the effect of esketamine on dynamic brain glutamate release, resting state connectivity, and neuroplasticity as measured via fMRS, BOLD-rs-fMRI, and a behavioural computerised visual task respectively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glutamate Emotion Memory Study

NCT05809609

Treatment Resistant Depression Depression Major Depressive Disorder

RECRUITING NA

Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI

NCT05320120

Ketamine Treatment

COMPLETED PHASE1

A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects

NCT02094378

Healthy

COMPLETED PHASE1

Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

NCT02049385

Depression

TERMINATED PHASE1/PHASE2

Brain Network Dynamics of Depression During Esketamine Treatment

NCT06012916

Depressive Disorder, Major

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is growing interest in the use of antagonists at the glutamate N-methyl-D-aspartate (NMDA) receptor in patients with treatment-resistant depression (TRD). Work in animal studies suggests that NMDA receptor antagonists act initially by increasing brain glutamate release, but whether such an action occurs in humans is not established.

Esketamine is the S-enantiomer of racemic ketamine: a non-selective, non-competitive, antagonist of the ionotropic glutamate NMDA receptor. It is the only NMDA receptor antagonist licensed in the UK for the treatment of patients with TRD. Esketamine is administered intranasally: it is rapidly absorbed by the nasal mucosa following nasal administration and can be measured in plasma within 7 minutes following a 28 mg dose. The time to reach maximum plasma concentration (tmax) is typically 20 to 40 minutes after the last nasal spray of a treatment session. It is hypothesised that through NMDA receptor antagonism, esketamine produces a transient increase in glutamate release leading to increases in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor stimulation and subsequently to increases in neurotrophic signalling which may contribute to the restoration of synaptic function, neuroplasticity, and connectivity in brain regions involved with the regulation of mood.

Glutamate is the primary excitatory neurotransmitter in the brain and has been implicated in several neuropsychiatric disorders. "Gold-standard" methods to assess glutamate activity in the living human brain are expensive and involve radioactive injections and invasive blood sampling. More recently, preliminary work in our Clinical Psychopharmacology laboratory (Department of Psychiatry, University of Oxford) has shown that 7T fMRS (a more widely available, non-invasive, safe technique) that uses a visual stimulus ("flickering checkerboard") can reliably and sensitively measure changes in brain glutamate release. No prior study however has shown whether this effect is susceptible to pharmacological challenge. We therefore propose to assess whether through its NMDA/AMPA-mediated activity, esketamine induced glutamate increase can be measured via this fMRS technique.

The aims of this study are to investigate the effect of esketamine on brain glutamate release and resting state connectivity, and on vision. Therefore, the primary objective of this study is to assess the effect of a single dose of esketamine 56mg intranasal vs placebo on brain glutamate release changes measured via 7T fMRS "flickering checkerboard" stimulus. Secondary objectives include the investigation of the effects of esketamine on brain resting state connectivity changes measured via 7T BOLD-rs-fMRI, and on vision measured via a behavioural computerised visual task. Psychological questionnaires will also be measured to check for possible correlations with the outcomes measured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Within-subject, cross-over design

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Self-administered by the participant wearing an eye mask, following instructions and under supervision of appropriately trained medical staff where resuscitation facilities are available, via a single-use device delivering 28 mg as two sprays (i.e., one spray per nostril).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Esketamine

Nasal spray solution, 56mg (28mg per nostril), intranasal

Group Type EXPERIMENTAL

Esketamine nasal spray

Intervention Type DRUG

Nasal spray solution, 56mg (28mg per nostril), intranasal

Placebo

Nasal spray solution, 0.9% NaCl, intranasal

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Nasal spray solution, 0.9% NaCl, intranasal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esketamine nasal spray

Nasal spray solution, 56mg (28mg per nostril), intranasal

Intervention Type DRUG

Placebo

Nasal spray solution, 0.9% NaCl, intranasal

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 to 50 years
* Body Mass Index in the range of 18-30
* Sufficiently fluent in English to understand the study instructions
* Willing and able to give informed consent for participation in the research

Exclusion Criteria

* Currently on any regular prescribed medications (except the contraceptive pill), unless unlikely to compromise safety or affect data quality in the opinion of the Investigator
* Known hypersensitivity to the study drug (i.e., esketamine)
* History of, or current significant alcohol or substance misuse disorder
* Any use of recreational drugs over the last 3 months
* Any lifetime use of ketamine or phencyclidine (PCP)
* Currently smoking \>/=20 cigarettes/day
* History of, or current significant cardiovascular disorder (e.g., hypertension, myocardial infarction)
* History of, or current significant neurological disorder (e.g., epilepsy, migraine) or cerebrovascular disorder (e.g., haemorrhagic or ischemic stroke, aneurysmal vascular disease, raised intracranial pressure)
* History of, or current significant respiratory, hepatic, urinary tract, or thyroid disorders
* History of, or current acute porphyria
* History of, or current significant psychiatric disorder (e.g., psychosis, mania, depression)
* History of, or current eye disorder, not including refractive error that can be corrected with glasses or contact lenses)
* Pregnant, breast feeding, women of child-bearing potential not using appropriate contraceptive measures
* Any contraindication to 7T MRI

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes